Klastersky J
Semin Oncol. 1985 Mar;12(1 Suppl 2):17-20.
The EORTC Lung Cancer Working Party investigated the effects of combination therapy with VP-16 (Ve-Pesid) and cisplatin in the treatment of non-small-cell lung cancer (NSCLC). Neither agent alone is recognized as being associated with a high rate of response in NSCLC, but the combination proved beneficial in our hands and effected a total response rate (including complete and partial responses) of over 40%. In addition to this encouraging result, complete remissions occurred in a modest number of patients. The addition of vindesine to the regimen profferred no benefit, but did increase the incidence of toxic reactions. Preliminary data on supraconventional dosages of cisplatin indicate a trend toward better response and longer survival but a significantly higher frequency of severe leukopenia as well. No studies have yet been conducted with higher doses of VP-16 in NSCLC patients, but related investigations into the treatment of small-cell bronchogenic carcinoma indicated that doses up to 3 g/m2 of VP-16 were well tolerated by patients. It is cautiously concluded that the combination of cisplatin and VP-16 probably offers an advantage over single-drug therapy with either agent alone in the treatment of non-small-cell lung cancer.
欧洲癌症研究与治疗组织肺癌工作组研究了依托泊苷（威猛）和顺铂联合治疗非小细胞肺癌（NSCLC）的效果。两种药物单独使用时，均未被认为与非小细胞肺癌的高缓解率相关，但在我们的研究中，联合治疗被证明是有益的，总缓解率（包括完全缓解和部分缓解）超过40%。除了这一令人鼓舞的结果外，还有相当数量的患者实现了完全缓解。在治疗方案中加入长春地辛并无益处，但确实增加了毒副反应的发生率。关于超常规剂量顺铂的初步数据表明，缓解趋势更好，生存期更长，但严重白细胞减少的发生率也显著更高。尚未对非小细胞肺癌患者使用更高剂量的依托泊苷进行研究，但对小细胞支气管癌治疗的相关调查表明，患者对高达3 g/m² 的依托泊苷剂量耐受性良好。谨慎得出的结论是，在非小细胞肺癌的治疗中，顺铂和依托泊苷联合使用可能比单独使用任何一种药物的单药治疗更具优势。
